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Abstract
A large number of patients suffering from oesophageal adenocarcinomas do not respond to conventional chemotherapy;
therefore, it is necessary to identify new predictive biomarkers and patient signatures to improve patient outcomes and
therapy selections. We analysed 87 formalin-fixed and paraffin-embedded (FFPE) oesophageal adenocarcinoma tissue
samples with a reverse phase protein array (RPPA) to examine the expression of 17 cancer-related signalling molecules.
Protein expression levels were analysed by unsupervised hierarchical clustering and correlated with clinicopathological
parameters and overall patient survival. Proteomic analyses revealed a new, very promising molecular subtype of
oesophageal adenocarcinoma patients characterised by low levels of the HSP27 family proteins and high expression of
those of the HER family with positive lymph nodes, distant metastases and short overall survival. After confirmation in other
independent studies, our results could be the foundation for the development of a Her2-targeted treatment option for this
new patient subgroup of oesophageal adenocarcinoma.
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Introduction
In the last 10 to 20 years, the incidence of adenocarcinomas
arising in the oesophagus has increased faster than that of any
other malignancy in the Western world [1–4]; in fact, oesophageal
adenocarcinoma is currently the seventh most frequent cause of
cancer mortalities in these populations [5]. Most patients have a
poor prognosis with a 5-year overall survival rate of approximately
25% and unfortunately, this disease is often not diagnosed until it
has reached the advanced stages and the tumour has metastasised.
Thus, multimodal treatment approaches with preoperative
cisplatinum/5-fluorouracil-based chemotherapy or radio-chemo-
therapy followed by resection are commonly used to improve the
survival of patients with oesophageal adenocarcinoma [6].
Recently, some studies have demonstrated a survival benefit for
patients that receive peri-operative chemotherapy compared with
those that undergo surgery alone for these tumours [7,8].
However, only 30% to 50% of these patients respond to
chemotherapy. For this reason, targeted therapies are in high
demand.
Therefore, the focus of this manuscript is on the identification
and analysis of new protein signatures for the optimisation of
therapy selection to avoid inefficient therapy, toxic side effects and
high costs.
In the last few years, the reverse phase protein array (RPPA) has
been shown to be valuable for the molecular classification of
tumours and the accurate assessment of prognoses and treatment
responses. RPPA represents a new high-throughput technology
that monitors changes in protein expression over time, before and
after treatments, between disease and non-disease states and
between responders and non-responders [9].
In this study, we analysed the expression profiles of 17 cancer-
related signalling pathway molecules in a series of 87 formalin-
fixed and paraffin-embedded (FFPE) oesophageal adenocarcino-
ma tissue samples by RPPA. We correlated the protein expression
patterns with specific clinicopathological parameters and overall
patient survival and found that high levels of HER2 and low levels
of p-HSP27
(Ser15) are correlated with an increased risk of death in
patients with oesophageal adenocarcinoma. These findings may
assist in the optimisation of patient-specific therapy selection and
should provide a basis for the development of new and more
effective treatment options for these patients.
Results
Unsupervised hierarchical cluster analysis of 87
oesophageal carcinomas
HER2 is a proto-oncogene that is frequently over-expressed in
breast cancer and has also recently been found to be over-
expressed in carcinomas arising from Barrett’s oesophagus and to
be correlated with poor survival. Thus, we analysed the proteins of
the HER-family (EGFR, p-EGFR, HER2, p-HER2, HER3, p-
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important roles in general tumour progression (Akt, p-Akt, Erk,
pErk), especially in breast cancer (uPA, PAI-1). In addition, we
examined the expression of the heat shock protein HSP27 and its
phosphorylated forms (Ser15, Ser78, Ser82) to assess whether the
observed link of HSP27 and HER2 in breast cancer cases is also
true in oesophageal carcinoma. Using RPPA, we analysed the
expression levels of these 17 proteins in 87 oesophageal
adenocarcinomas. To obtain deeper insight into the relationships
between these proteins and reveal potential overlaps in their
signalling pathways, we performed unsupervised hierarchical
clustering to generate a depiction of the tumour-specific protein
network. As shown in Figure 1, the patient cluster formation
revealed three groups with different expression profiles. In Cluster
3, a significantly lower amount of tumours were lymph node (24%
vs. 64%; p,0.05) or distant metastases positive (0% vs. 13%;
p,0.05) compared to combined Cluster 1 and 2. However there
were no significant differences in the distribution of relevant
clinical parameters (TNM-classification, grading and Lauren’s
classification) between Cluster 1 and 2.
Association of heat shock protein 27
(Ser15) and HER2
expression and survival
Next, we wanted to determine if some of the analysed proteins
had a greater prognostic value in patients with oesophageal
adenocarcinoma than others. Thus, we analysed all 17 of the
signalling proteins using maximally selected log-rank statistic
method [10] of quantitative protein expression in combination
with Cox-regression, which allow for optimised risk prediction.
Only proteins that showed both, a significant log-rank test for the
optimal cut-off value and a significant test for the Cox regression
coefficient of the corresponding continuous variable were seen as
reliable. Optimal cut-off values could be established for HER2 and
p-HSP27
(Ser15) (1316 MicroVigene signal intensity points (MVS)
for p-HSP27
(Ser15) and 1276 MVS for HER2, respectively; see
Figure S1). HER2-negative patients that were characterised by
MVS values of less than 1276 had median survival times of 38.9
months, whereas it was 29.5 months for patients with MVS values
of greater than 1276 (p=0.017; log-rank test, Figure 2A).
Interestingly, patients with high p-HSP27
(Ser15) levels (MVS.
1316) also showed prolonged survival (survival rates of 0.7 at 50
months compared with 0.38 for patients with low p-HSP27
(Ser15)
expression levels; p=0.007, log-rank test Figure 2B). A
multivariate Cox regression analysis revealed that HER2 and p-
HSP27
(Ser15) are prognostic factors for survival independent of
those that have already been established, such as depth of tumour
invasion (UICC pT category), presence of lymph node metastases
(UICC pN category) and presence of distant metastases at the time
of resection (UICC cM category) (see Table 1). This relationship
is also illustrated by a nomogram in Figure S2.
Narrowed, unsupervised hierarchical cluster analysis of
87 oesophageal adenocarcinomas
Because p-HSP27
(Ser15) and HER2 showed prognostic value to
the clinical outcome for oesophageal adenocarcinoma patients, we
performed a second hierarchical cluster analysis of the investigated
members of the HSP27 group (HSP27; p-HSP27
(Ser15);p -
HSP27
(Ser78); p-HSP27
(Ser82)) and the HER family proteins
(EGFR, HER2, HER3, HER4, pEGFR, p-HER2, p-HER3).
Two clusters (Cluster A and B) could be distinguished by their
protein expression patterns. Cluster A consisted of proteins from
the HER family, whereas Cluster B was comprised of HSP27 and
its phosphorylated forms (abbreviated as ‘‘(p)HSP27’’). Two
clusters, named Clusters 1 and 2, could be identified from the
patient samples (see Figure 3). Cluster 1 was composed of
tumours that over-expressed (p)HSP27 group proteins and showed
low expression levels of HER family proteins, whereas Cluster 2
showed the opposite profile (high levels of proteins from the HER
family and low levels of those from the (p)HSP27 group). There
were significant differences in relative frequency of distant
metastasis (0% vs. 15%) as well as positive lymph nodes (21%
vs. 67%) in favour of Cluster 1 (Figure 4A+B; For an overview of
the composition of the clusters and the p-value of all tested clinical
parameters between the two clusters see Table 2.). Accordingly, a
better survival was observed for cases of Cluster 1 (Figure 4C).
Therefore, considering p-HSP27
(Ser15) and HER2 as prognostic
factors, cluster analysis strengthen evidence that low levels of
(p)HSP27 are associated with poor patient prognosis, whereas
cases showing low levels of HER family proteins have a higher
probability of prolonged overall survival.
Discussion
Molecular profiling of tumour cell-protein networks in routinely
processed, clinical cancer tissue samples will be critical for
elucidating the process of cancer development and for response
prediction to various therapy regimes and targeted therapeutic
approaches. The reverse phase protein array (RPPA) represents an
emerging technology that is rapidly becoming a powerful tool for
the development of drugs and the signal transduction profiling of
cellular material. A big benefit of RPPA lies in its ability to
generate a patient specific ‘‘map’’ of signalling networks. The
RPPA technology is a new, high-throughput technology that
monitors changes in protein phosphorylation over time, before
and after treatment, between disease and non-disease states and
between responders and non-responders [9]. Moreover, it is
suitable for the signal transduction profiling of small numbers of
cultured cells or cells that are isolated by laser capture
microdissection from human biopsies [11,12]. After protein
extraction, each patient sample is arrayed in triplicate on
nitrocellulose-coated slides using a miniature dilution curve. Thus,
each analyte/antibody combination can be analysed in the linear
dynamic range [9,13].
In the present study, we have applied this technology to find
new protein signatures of oesophageal adenocarcinoma that may
place patients into different groups based on their protein
expression profiles to improve patient-specific therapy selection.
We discovered two new molecular subtypes of oesophageal
adenocarcinoma patients (Figure 3). The first subtype (Cluster1)
is characterised by high (p)HSP27 protein levels (cut-off: 1316),
low levels of HER family proteins (cut-off: 1276), negative lymph
node status, negative distant metastasis status and prolonged
overall survival. In contrast, the second subtype (Cluster 2) is
defined by low levels of (p)HSP27 and high levels of HER family
proteins. Additionally, this subtype showed positive lymph nodes,
positive distant metastasis status and short overall survival times.
Furthermore, we were able to identify p-HSP27
(Ser15) and HER2
as independent prognostic factors in consideration of established
survival predictors (such as depth of tumour invasion, presence of
lymph node metastases and presence of distant metastases at the
time of resection). The found fact that HER2 over-expression or
amplification predicts poor survival has been seen in many cancer
types such as breast cancer [14,15,16,17] or oesophageal
adenocarcinomas [18,19], whereas to our knowledge no studies
showed an influence of p-HSP27
(Ser15) in human tumour tissue.
However some previous studies showed that HSP27 over-
expression is associated with a good prognosis in squamous cell
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Additionally, low pre-therapeutic HSP27 protein expression was
associated with poor tumour responses to neo-adjuvant chemo-
therapy in oesophageal adenocarcinomas [22].
Although the expression profiles of (p)HSP27 proteins and those
of the HER family in oesophageal adenocarcinoma have been
studied in the recent years, no study has addressed a possible
association between these two molecules. However, in breast
cancer patients, the cellular functions of HSP27 that is
phosphorylated at various sites (Ser78, Ser82 and Ser15) have
been analysed, and it was shown that the phosphorylation of
HSP27 at Ser78 but not at Ser15 or Ser82 was significantly
correlated with positive HER2 and lymph node status [23]. Most
interestingly, Kang et al. demonstrated that the suppression of
HSP27 by specific siRNA increased the susceptibility of SK-BR-3
to trastuzumab [24]. In our study, we were able to demonstrate
that although p-HSP27
(S15) and HER2 were independent
prognostic factors for survival, their expression levels were
interrelated in oesophageal adenocarcinoma.
These findings open up new possibilities for the effective
treatment of oesophageal adenocarcinoma patients. One major
problem has been that, as mentioned above, oesophageal
adenocarcinoma patients with low HSP27 levels are resistant to
chemotherapy. However, most of these patients show high HER2
expression levels, which suggest that a HER2-specific therapy,
such as trastuzumab, may be optimal for these patients.
Additionally, a study by Kang et al. [24] showed that the
suppression of HSP27 by specific siRNA increased the suscepti-
bility of human breast cancer cells to trastuzumab. Therefore,
HER2-targeted treatments could lead not only to fewer side effects
but also, more importantly, to higher response rates for low
HSP27-expressing tumours. In support of our findings, the ToGA
study recently showed that trastuzumab in combination with
chemotherapy was effective in the treatment of gastric and gastro-
oesophageal junction cancers [25]. However, this type of therapy
remains to be validated in oesophageal adenocarcinoma patients.
Materials and Methods
Ethics Statement
All patients gave informed written consent, and the study was
approved by the Ethics Committee of the Technische Universita ¨t
Mu ¨nchen, Munich, Germany.
Tissue samples
Formalin-fixed, paraffin-embedded oesophageal adenocarcino-
ma tissues from 87 patients diagnosed between 1990 and 2005
were selected from the archive at the Institute of Pathology,
Technische Universita ¨tMu ¨nchen, Germany. Pathological param-
eters were defined according to the recommendations of the WHO
and UICC TNM classification [26]. The patients received neither
neo-adjuvant nor adjuvant treatments. Reference haematoxylin/
eosin stained sections of the tissues were histologically verified by
an experienced pathologist (RL). Only tissue sections containing
Figure 1. Hierarchical cluster analysis of 87 oesophageal
adenocarcinoma cases according to the expression of 17
signalling molecules. Three clusters could be found. However in
regard to the expression profile no distinct difference could be
detected. Cluster colour key: Red – up-regulated; green – down-
regulated; black – unchanged; grey – missing.
doi:10.1371/journal.pone.0023985.g001
New Subtypes in Oesophageal Adenocarcinoma
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e23985more than 80% tumour cells were included in the study. For
detailed information about the collective, see Table 2.
Antibodies
Table 3 lists the proteins analysed and antibodies used in
the reverse phase protein arrays. All antibodies were validated
by western blot using proteins extracted from formalin-fixed
tissues (data not shown, for HER2 and p-HSP27
(Ser15)
antibodies see Figure S3).
Protein extraction
The protein extraction was performed as previously described
[27]. Briefly, tissue sections were deparaffinised and proteins were
extracted using EXB Plus. Tumour tissue (containing at least 80%
tumour cells) was microdissected and approximately 0.5 cm
2 tissue
from three 10 mm thick sections were processed in 100 mlo f
extraction buffer. Protein concentrations were determined using
the Bradford protein assay according to the manufacturer’s
instructions (BioRad, Hercules, CA). Randomly selected lysates
Figure 2. Kaplan-Meier survival curves for patients with A) high versus low HER2 protein expression levels (MicroVigene Signal
intensity cut-off level of 1276) and B) high) versus low p-HSP27
(Ser15) expression levels (MicroVigene Signal intensity cut-off level
of 1316). Statistical significance of differences between groups was evaluated with the log-rank test.
doi:10.1371/journal.pone.0023985.g002
Table 1. Multivariate Cox regression analyses for p-HSP27
(Ser15), HER2, pT, pN and cM.
95%-CI
Hazard Ratio*
coeff hazard ratio lower upper p-value
p-HSP27
(Ser15) continuous 20.0777 0.93 0.88 0.97 0.0007
HER2 continuous 0.0328 1.03 1.01 1.06 0.0021
pT2 vs. pT1 12.761 3.58 1.22 10.54 0.0204
pT3 vs. pT1 0.9942 2.70 0.95 7.72 0.0635
pN1 vs. pN0 0.6779 1.97 0.87 4.47 0.1051
cM1 vs. cM0 0.5587 1.75 0.67 4.55 0.2528
95%-CI
Hazard Ratio*
coeff hazard ratio lower upper p-value
HSP27Ser15 neg vs. pos
{ 1.5029 4.49 1.35 15.00 0.0145
HER2 pos
# vs. neg 0.6757 1.97 1.01 3.82 0.0465
pT2 vs. pT1 1.0864 2.96 1.02 8.60 0.0457
pT3 vs. pT1 0.8143 2.26 0.77 6.63 0.1387
N1 vs. N0 0.7399 2.10 0.89 4.92 0.0894
M1 vs. M0 0.5089 1.66 0.67 4.13 0.2727
*Risk ratios (hazard ratios) and their lower and upper 95% confidence limits apply for the units of measure in question.
{p-HSP27
(Ser15) positive .1316.
#HER2 positive .1276.
Statistically significant p-values are marked in bold letters. pT: tumour status as determined in pathology; pN: lymph node status as determined in pathology; cM:
occurrence of distant metastases as determined by attending physician.
doi:10.1371/journal.pone.0023985.t001
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the protein extraction and suitability of the material for the reverse
phase protein array analysis. All protein lysates that were analysed
showed a clear b-actin band on the western blot.
Reverse phase protein arrays
Reverse phase protein arrays were generated using the
Calligrapher MiniArrayer (BioRad, Hercules, CA) according to
the manufacturer’s instructions. For a general description of the
procedure, see references [28,29]. In the present study, for every
lysate and every dilution (undiluted, 1:2, 1:4, 1:8, 1:16, buffer),
three replicates were applied onto a nitrocellulose-coated glass
slide (Grace Bio-Labs, Bend, OR) and 3*6=18 data points per
sample were obtained. Peroxidase blocking was performed
according to the manufacturer’s instructions (Dako, Glostrup,
Denmark). Immunodetection was performed similar to a western
blot and as previously described [30]. For the estimation of the
total protein amounts, parallel arrays were stained with Sypro
Ruby Protein Blot Stain (Molecular Probes, Eugene, OR)
according to the manufacturer’s instructions.
Quantitative protein analysis
The tif images for the antibody-detected slides and Sypro Ruby-
stained slides were analysed with MicroVigene 3.5.0.0 (Vigene-
Tech, Carlisle, MA). The MicroVigene signal-intensity points
(MVS) were calculated by the integral of a logistic 4-point fit
model that was matched optimally to the 3*6 data points that were
obtained.
Statistical analysis
Unsupervised hierarchical clustering. Unsupervised hie-
rarchical clustering was performed with the Cluster and TreeView
softwares. Following log transformation and centre to median
calculations, average hierarchical clustering was performed using
the Spearman rank correlation [31].
Survival analysis. Statistical analyses were conducted using
R Software version 2.11.1 (R Foundation for Statistical Com-
puting, Vienna, Austria). To derive optimal cut-off values of
quantitative protein expressions that may allow for useful risk
predictions, maximally selected log-rank statistics were used. To
consider multiple test issues within these analyses, the R-function
‘maxstat.test’ was employed [10].
In addition, survival rates were estimated according to the
Kaplan-Meier method. Statistical comparisons between the
different patient subgroups were conducted with the log-rank
test. Multivariate survival analyses were performed using the Cox
proportional hazards regression for HER2 and p-HSP27
Ser15
together with the clinical variables such as depth of tumour
invasion (UICC pT category), presence of lymph node metastases
(UICC pN category) and presence of distant metastases at the
time of resection (UICC cM category) including risk ratios and
95% CI.
Correlation analysis and group comparison. For con-
tinuous variables, bivariate relationship was assessed by using
Figure 3. Narrowed hierarchical cluster analysis. The 87
oesophageal adenocarcinoma cases were clustered according to the
expression of the investigated members of the (p)HSP27 group and the
HER family. Two tumour clusters could be found. Cluster 1 was
composed of mainly low HER2-family and high (p)HSP27-group
expressing cases, whereas Cluster 2 showed a reverse pattern. Cluster
colour key: Red – up-regulated; green – down-regulated; black –
unchanged; grey – missing.
doi:10.1371/journal.pone.0023985.g003
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overall survival. Cluster 1, which mainly consisted of low HER2 family and high (p)HSP27 group-expressing cases was comprised of few pN (21%)
and no cM (0%) positive cases, whereas Cluster 2 (high HER2 family and low (p)HSP27 group) was comprised of significantly more pN- and cM-
positive cases (67% and 15%, respectively). Consistent with these data, patients in Cluster 1 had significantly better overall survival times than Cluster
2.
doi:10.1371/journal.pone.0023985.g004
Table 2. Patient and disease characteristics related to the collective used in this study and to the two found clinical relevant
clusters.
Factor No. of patients (%) collective No. of patients (%) Cluster 1 No. of patients (%) Cluster 2 p-value
Total 87 (100) 33 (100) 54 (100)
Age
mean 63 63 64
range 33–82 33–82 38–80 0.514
Gender
female 8 (9) 2 (6) 6 (11)
male 79 (91) 31 (94) 48 (89) 0.513
pT category
pT1 29 (33) 14 (42) 15 (28)
pT2 19 (22) 7 (21) 12 (22)
pT3 39 (45) 12 (37) 27 (50) 0.337
pN category
negative 44 (51) 26 (79) 18 (33)
positive 43 (49) 7 (21) 36 (67) 3.9*10
25
Metastasis
cM0 79 (91) 33 (100) 46 (85)
cM1 8 (9) 0 (0) 8 (15) 0.020
Grading
G1 1 (1) 1 (3) 0 (0)
G2 41 (47) 16 (49) 25 (46)
G3 45 (52) 16 (48) 29 (54) 0.414
pT category: depth of tumour invasion; pN category: presence of lymph node metastases; cM category: presence of distant metastases at the time of resection (all
classification according to UICC). The p-values for cluster comparison using Chi
2-test (for age Mann-Whitney U test) are given. Significant differences were found for
lymph node and distant metastases status (bold).
doi:10.1371/journal.pone.0023985.t002
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results were clinically relevant, only moderate consistent
correlations of |rs|.0.40 were considered. For comparisons of
frequency distributions between independent subgroups Chi-
square test was performed.
Supporting Information
Figure S1 Maximally selected log-rank statistics of
quantitative protein expression of all 17 analysed
signalling proteins to assess the presence of useful risk
predictions. Although in this univariate categorical analysis
statistically significant cut-off values could be determined for
HER2, p-HSP27
(Ser15), Erk and p-HSP27
(Ser82), these results were
not confirmed in the Cox-regression analysis for Erk and
HSP27
(Ser82). Therefore credible risk prediction was only possible
for the continuous marked proteins (Her2 and p-HSP27
(Ser15)).
Significance level of the log-rank statistics are marked by the
horizontal line. The p-values of Cox-regression are given for
HER2, p-HSP27
(Ser15), Erk and p-HSP27
(Ser82). Cut-off values are
marked by the vertical dashed line.
(TIF)
Figure S2 Illustration of the influence of HER2, p-
HSP27
(Ser15), pT, pN and cM levels on survival. High
expression levels of HER2, low levels of p-HSP27
(Ser15) and high
TNM levels resulted in high numbers of total risk-points and
therefore short survival probabilities for the patients. The survival
probability of a specific patient may be determined as follows: first,
the risk points for each parameter (HER2, p-HSP27
(Ser15), pT, pN,
cM) are to be identified separately. Thus, the value of the
parameters must be matched to the risk point chart (e.g., if HER2
was calculated to be 4000, the corresponding risk points would be
45). To get the total risk point value, the risk points of all five of the
parameters must be added up. These total risk points are then used
to map the estimated survival probabilities by matching them with
the survival probability chart (e.g., a total risk point value of 120
would result in an estimated 6 month survival probability of 0.8.)
[32,33].
(TIF)
Figure S3 Validation of HER2 and p-HSP27
(S15) anti-
bodies for use in RPPA. Both antibodies showed high
specificity, which is required for the RPPA analysis. To work
with the tissue used in the RPPA analysis both western blots were
performed with oesophageal adenocarcinoma FFPE tissue.
(TIF)
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